Study finds association between painkillers in pregnancy and male reproductive problems

Using mild painkillers in pregnancy appears to raise the risk of cryptorchidism (undescended testicles) in baby boys, new EU-funded research suggests. The findings offer an explanation of why cryptorchidism, which is the biggest risk factor for poor semen quality and testicular cancer in later life, is becoming more common.

The study is published online in the journal Human Reproduction. EU support for the work came from the DEER ('Developmental effects of environment on reproductive health') and CONTAMED ('Contaminant mixtures and human reproductive health - novel strategies for health impact and risk assessment of endocrine disrupters') projects, which each received EUR 3.5 million under the Environment Theme of the Seventh Framework Programme (FP7).

Rates of cryptorchidism are on the rise; in Denmark, just 1.8% of newborn boys were affected in 1959-1961, but by 1997-2001 that figure had risen to 8.5%. Studies in rats have suggested that cryptorchidism may be caused by a lack of male sex hormones during a particular period of pregnancy. So-called endocrine disruptors, molecules that interfere with or block the action of hormones, are thought to be behind the problem. However, tracking down these endocrine disruptors has proven difficult. Some studies have pointed to certain common painkillers, namely aspirin, paracetamol and ibruprofen, which may reduce testosterone production and could act as endocrine disruptors.

In this study, the scientists set out to study the influence of mild analgesics on male reproductive disorders in both humans and rats.

For the human part of the study, the scientists quizzed over 2,000 pregnant women in Denmark and Finland on their use of medication during pregnancy. The baby boys were examined at birth by paediatricians who looked for signs of cryptorchidism and graded any cases found according to their severity.

The results were clear; women who had used more than one kind of painkiller at the same time were seven times more likely to give birth to a son with some form of cryptorchidism than a woman who had not taken painkillers.

The second trimester appears to be a particularly sensitive time; taking any painkiller during this time more than doubled the risk of cryptorchidism, and taking more than one kind of painkiller during the second trimester increased the risk 16-fold.

Studies in rats confirmed that analgesics do indeed disrupt the production of androgens, resulting in a lack of testosterone during the period of pregnancy when the male sex organs are formed. According to the researchers, mild analgesics effectively halved testosterone levels in the testes of unborn rats.

The findings are important because around half of pregnant women in Europe and the US report taking mild painkillers, usually paracetamol.

"If exposure to endocrine disruptors is the mechanism behind the increasing reproductive problems among young men in the western world, this research suggests that particular attention should be paid to the use of mild analgesics during pregnancy, as this could be a major reason for the problems," commented Dr Henrik Leffers of the Rigshospitalet in Copenhagen, Denmark, who led the research.

"A single paracetamol tablet (500 mg) contains more endocrine disruptor potency than the combined exposure to the ten most prevalent of the currently known environmental endocrine disruptors during the whole pregnancy," Dr Leffers added.

"In fact, a single tablet will, for most women, be at least a doubling of the exposure to the known endocrine disruptors during the pregnancy and that dose comes on a single day, not spread out over nine months as with the environmental endocrine disruptors. Thus, for women using mild analgesics during the pregnancy, the mild analgesics will be by far the largest exposure to endocrine disruptors."

The team note that more research is needed into this issue; for their part, they will continue to monitor the boys born during the study, who are now entering puberty.

On the issue of whether pregnant women should take painkillers or not, Dr Leffers says: "As biologists this is not something we can advise women about. So we recommend that pregnant women seek advice from their physician before using mild analgesics and in general follow the advice to use as little medicine during pregnancy as possible."

For further information, please visit:

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...